In CY 2024, four of these qualifying nonopioid products were separately payable without the 18 percent payment limitationHCPCS Codes C9089 (Bupivacaine implant, 1 mg), J0666 (Inj, bupivacaine liposome), J1096 (Dexametha opth insert 0.1 mg), and J1097 (Phenylep ketorolac opth soln)
The same applies to vendor communications review materials carefully to avoid things like language that ties weight to personal worth, or humor that reinforces negative biases
This creates an opportunity for brands to design products that deliver controlled, functional outcomes rather than only lower sugar content. Cargill emphasizes the need for integrated systems that unite ingredient innovation, data-driven formulation, and application expertise to produce scalable, consistent, and consumer-aligned solutions
And what the paradigm shift is we are looking at not just obesity being a disease based on body mass index
Q5: How does CagriSema compare to tirzepatide
doi: 10.1159/000480525